Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa
The HiSQOL subscale and total scores demonstrated robust psychometric properties, supporting the use of HiSQOL to interpret trial results and inform treatment decisions.
Authors
- Joslyn S. Kirby (ORCID: https://orcid.org/0000-0002-6741-3796)
- Robert Rolleri
- Valérie Ciaravino
- Linnea Thorlacius (ORCID: https://orcid.org/0000-0002-3734-9607)
- John R Ingram (ORCID: https://orcid.org/0000-0002-5257-1142)
- Jérémy Lambert (ORCID: https://orcid.org/0000-0002-7164-1492)
- C. Pelligra (ORCID: https://orcid.org/0000-0002-5255-2777)
- Ingrid Pansar
- Edward Muller
Institutions
- Ithaka Harbors (US)
- University of Copenhagen (DK)
- Zealand University Hospital (DK)
- UCB Pharma (France) (FR)
- UCB Pharma (United States) (US)
- UCB Pharma (United Kingdom) (GB)
- Cardiff University (GB)
- Penn State Milton S. Hershey Medical Center (US)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1093/bjd/ljaf067
- Citations
- 2
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01